- Home
- GENK vs AIMD Comparison
GENK vs AIMD Comparison
Compare GENK & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- AIMD
- Stock Information
- Founded
- GENK 2011
- AIMD 1984
- Country
- GENK United States
- AIMD United States
- Employees
- GENK N/A
- AIMD N/A
- Industry
- GENK Restaurants
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- AIMD Health Care
- Exchange
- GENK Nasdaq
- AIMD Nasdaq
- Market Cap
- GENK 16.3M
- AIMD 16.9M
- IPO Year
- GENK 2023
- AIMD N/A
- Fundamental
- Price
- GENK $2.49
- AIMD $1.81
- Analyst Decision
- GENK Strong Buy
- AIMD
- Analyst Count
- GENK 2
- AIMD 0
- Target Price
- GENK $7.00
- AIMD N/A
- AVG Volume (30 Days)
- GENK 60.5K
- AIMD 43.3K
- Earning Date
- GENK 11-07-2025
- AIMD 11-13-2025
- Dividend Yield
- GENK 1.20%
- AIMD N/A
- EPS Growth
- GENK N/A
- AIMD N/A
- EPS
- GENK N/A
- AIMD N/A
- Revenue
- GENK $217,449,000.00
- AIMD $113,037.00
- Revenue This Year
- GENK $12.35
- AIMD N/A
- Revenue Next Year
- GENK $14.62
- AIMD N/A
- P/E Ratio
- GENK N/A
- AIMD N/A
- Revenue Growth
- GENK 9.36
- AIMD 178.19
- 52 Week Low
- GENK $2.31
- AIMD $1.84
- 52 Week High
- GENK $9.04
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- GENK 39.21
- AIMD 25.02
- Support Level
- GENK $2.31
- AIMD $1.89
- Resistance Level
- GENK $2.85
- AIMD $2.28
- Average True Range (ATR)
- GENK 0.19
- AIMD 0.22
- MACD
- GENK -0.02
- AIMD -0.09
- Stochastic Oscillator
- GENK 30.99
- AIMD 6.03
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.